 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's
terms of use. It may require cleanup to comply with Wikipedia's
content policies, particularly
neutral point of view. (June 2019) |
 | |
| Company type | Allmennaksjeselskap |
|---|---|
| OSE: PHO | |
| Industry | Pharmaceutical |
| Founded | 1993 |
| Headquarters | Oslo, Norway |
Key people | Daniel Schneider ( CEO), Jan Egberts ( Chairperson of the board) |
| Products |
Hexvix Cysview |
| Revenue | NOK 150 million [1] |
Number of employees | 70 |
| Website | www.photocure.com |
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy.[ citation needed]
Pharmaceuticals
Hexyl aminolevulinate hydrochloride for diagnosis of bladder cancer.
References
- ^ Photocure Annual Report 2010 Archived 2012-03-15 at the Wayback Machine
External links
| This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's
terms of use. It may require cleanup to comply with Wikipedia's
content policies, particularly
neutral point of view. (June 2019) |
|
| |
| Company type | Allmennaksjeselskap |
|---|---|
| OSE: PHO | |
| Industry | Pharmaceutical |
| Founded | 1993 |
| Headquarters | Oslo, Norway |
Key people | Daniel Schneider ( CEO), Jan Egberts ( Chairperson of the board) |
| Products |
Hexvix Cysview |
| Revenue | NOK 150 million [1] |
Number of employees | 70 |
| Website | www.photocure.com |
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy.[ citation needed]
Pharmaceuticals
Hexyl aminolevulinate hydrochloride for diagnosis of bladder cancer.
References
- ^ Photocure Annual Report 2010 Archived 2012-03-15 at the Wayback Machine